Bioactivity and safety of B7-H3-targeted chimeric antigen receptor T cells against anaplastic meningioma.

ABSTRACT:

Objective

We conducted a first-in-human study to evaluate the bioactivity and safety of B7-H3-targeted chimeric antigen receptor (CAR) autologous T cells for treating recurrent anaplastic meningioma.

Methods

Tumor tissues from a patient with recurrent anaplastic meningioma were evaluated for B7-H3 expression. B7-H3-targeted CAR-T cells were delivered into the intracranial tumor resection cavity using an Ommaya device at a maximum dose of 1.5 × 10⁷ cells. Magnetic resonance imaging (MRI) screening and multiple serum indexes were regularly monitored. The patient received surgical intervention after three-cycle infusions, allowing analysis for CAR-T-cell infiltration and target antigen expression in post-CAR-T therapy tumor tissues.

Results

Immunochemical anal

SUBMITTER: Tang X 

PROVIDER: S-EPMC7292833 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature